is a global leader in generic pharmaceuticals and biosimilars and a division of
the Novartis Group. Sandoz contributes to society’s ability to support growing
healthcare needs by pioneering novel approaches to help people around the world
access high-quality medicine. That is our purpose. Our business ambition is to
be the world’s leading and most valued generics company.
Our global portfolio comprises approximately 1,000 molecules, covering all major therapeutic areas, which accounted for 2019 sales of USD 9.7 billion. Our broad offering translates into substantial and ongoing savings for patients and payors, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines.
Our products reach more than 500 million patients. Our broad portfolio is spearheaded by our global leadership position in both biosimilars, the “cutting edge” of innovative off-patent medicines, and generic antibiotics, the foundation of global healthcare systems. We also run a broad range of targeted corporate responsibility programs to increase access to medicine, medical information and appropriate medical training for healthcare professionals.
Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)
Primary business activity
Categories affiliated with Sandoz
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation